Skip to search formSkip to main contentSkip to account menu

KX2-391

Known as: KX01, Src Kinase Inhibitor KX2-391 
An orally bioavailable small molecule Src kinase inhibitor with potential antineoplastic activity. Unlike other Src kinase inhibitors which bind to… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Phase II study of KX2-391 ointment 1%, a novel field treatment for actinic keratosis, based on Src/tubulin polymerization inhibition
2017
2017
Targeting Src attenuates peritoneal fibrosis and inhibits the epithelial to mesenchymal transition
Src has been reported to mediate tissue fibrosis in several organs, but its role in peritoneal fibrosis remains unknown. In this… 
2017
2017
A phase 1b dose escalation study to evaluate safety, tolerability and pharmacokinetics of oral monotherapy with KX2-391 in elderly subjects with acute myeloid leukemia who are refractory to or have…
7043Background: Treatment of elderly AML patients is complicated by poor tolerance to standard therapies and multi-drug… 
2012
2012
Preclinical Development Peptidomimetic Src / Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth , Metastasis in Human ER / PR / HER 2-Negative Tumor Xenografts
Src kinase is elevated in breast tumors that are ER/PR negative and do not overexpress HER2, but clinical trials with Src… 
2012
2012
684 SITES AND SURVIVAL OF METASTATIC HEPATOCELLULAR CARCINOMA: ANALYSIS OF A NATIONWIDE INPATIENT DATABASE FROM THE UNITED STATES
2012
2012
A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer (CRPC): A PCCTC trial.
4654 Background: KX2-391 is an oral small molecule inhibitor of Src kinase and tubulin polymerization. In phase 1 trials, PSA… 
2010
2010
Abstract 2487: Mechanism of action KX01 (KX2-391), a novel tubulin polymerization and Src signaling inhibitor proceeding to Phase II clinical trials
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC KXO1 (KX2-391) has completed Phase I clinical… 
2010
2010
Abstract 2534: Suppression of prostate cancer growth by the Src signaling inhibitor, KXO1 (KX2-391)
KXO1 (KX2-391), developed as a Src tyrosine kinase signaling inhibitor, exhibits anti-proliferative activity against broad range… 
2006
2006
NORMAL CONDUCTING HIGH-GRADIENT STUDIES AT KEK
Normal-conducting high-frequency high-field studies have been pursued at XTF, which is a high power X-band RF facility of KEK… 
2004
2004
PROGRESS TOWARD NLC/GLC PROTOTYPE ACCELERATOR STRUCTURES*
The accelerator structure groups for NLC (Next Linear Collider) and GLC (Global Linear Colliders) have successfully collaborated… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)